184.84
price down icon2.27%   -4.42
after-market 시간 외 거래: 184.85 0.010 +0.01%
loading
전일 마감가:
$189.26
열려 있는:
$189.62
하루 거래량:
3.86M
Relative Volume:
0.57
시가총액:
$326.59B
수익:
$57.37B
순이익/손실:
$4.20B
주가수익비율:
78.66
EPS:
2.35
순현금흐름:
$15.39B
1주 성능:
-3.42%
1개월 성능:
-0.18%
6개월 성능:
+7.16%
1년 성능:
+7.34%
1일 변동 폭
Value
$184.63
$189.90
1주일 범위
Value
$184.63
$192.34
52주 변동 폭
Value
$163.81
$218.66

애브비 Stock (ABBV) Company Profile

Name
명칭
Abbvie Inc
Name
전화
(847) 932-7900
Name
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
직원
55,000
Name
트위터
@abbvie
Name
다음 수익 날짜
2025-04-25
Name
최신 SEC 제출 서류
Name
ABBV's Discussions on Twitter

ABBV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.89 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.66 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.40 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.18 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.94 306.33B 43.59B 15.04B 10.74B 3.3766

애브비 Stock (ABBV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-14 다운그레이드 Citigroup Buy → Neutral
2025-04-22 개시 Cantor Fitzgerald Overweight
2024-12-10 재개 BofA Securities Neutral
2024-12-05 다운그레이드 Daiwa Securities Outperform → Neutral
2024-11-22 업그레이드 Leerink Partners Market Perform → Outperform
2024-11-15 개시 Wolfe Research Outperform
2024-11-04 업그레이드 Argus Hold → Buy
2024-10-17 개시 Bernstein Mkt Perform
2024-06-05 업그레이드 HSBC Securities Hold → Buy
2024-05-17 개시 Cantor Fitzgerald Overweight
2024-01-29 업그레이드 William Blair Mkt Perform → Outperform
2023-12-18 다운그레이드 HSBC Securities Buy → Hold
2023-12-11 업그레이드 Goldman Neutral → Buy
2023-11-09 개시 Deutsche Bank Hold
2023-10-30 업그레이드 Barclays Equal Weight → Overweight
2023-10-20 재개 UBS Neutral
2023-09-29 개시 Raymond James Outperform
2023-07-25 개시 William Blair Mkt Perform
2023-07-14 개시 HSBC Securities Buy
2023-04-05 다운그레이드 Argus Buy → Hold
2023-03-01 개시 Guggenheim Buy
2023-02-22 다운그레이드 Wolfe Research Outperform → Peer Perform
2023-02-10 업그레이드 SVB Securities Underperform → Market Perform
2022-11-18 개시 Credit Suisse Outperform
2022-11-08 다운그레이드 Societe Generale Buy → Hold
2022-08-01 다운그레이드 Atlantic Equities Overweight → Neutral
2022-05-23 개시 SVB Leerink Underperform
2022-05-06 다운그레이드 Daiwa Securities Outperform → Neutral
2022-04-06 재개 Morgan Stanley Overweight
2022-02-28 다운그레이드 UBS Buy → Neutral
2022-02-03 재확인 BMO Capital Markets Outperform
2022-02-03 재확인 Barclays Equal Weight
2022-02-03 재확인 BofA Securities Neutral
2022-02-03 재확인 Goldman Neutral
2022-01-13 개시 Redburn Buy
2022-01-12 재확인 BMO Capital Markets Outperform
2021-12-09 재개 Wells Fargo Overweight
2021-11-23 업그레이드 Societe Generale Hold → Buy
2021-07-27 재개 Truist Buy
2021-04-07 재개 RBC Capital Mkts Outperform
2020-11-10 재개 Bernstein Outperform
2020-09-29 개시 Berenberg Hold
2020-06-23 업그레이드 Atlantic Equities Neutral → Overweight
2020-06-09 업그레이드 Wolfe Research Peer Perform → Outperform
2020-06-02 업그레이드 Argus Hold → Buy
2020-05-18 재개 BofA/Merrill Neutral
2020-05-12 업그레이드 JP Morgan Neutral → Overweight
2020-05-11 재개 Morgan Stanley Overweight
2020-04-20 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2020-03-23 다운그레이드 Societe Generale Buy → Hold
2020-02-27 개시 Barclays Equal Weight
2020-02-06 개시 Mizuho Buy
2020-01-07 개시 RBC Capital Mkts Sector Perform
2019-12-26 재확인 Cowen Outperform
2019-09-26 업그레이드 Citigroup Neutral → Buy
2019-08-20 업그레이드 Piper Jaffray Neutral → Overweight
2019-06-27 업그레이드 Wolfe Research Underperform → Peer Perform
2019-06-26 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-05-28 개시 Goldman Neutral
2019-04-29 업그레이드 BMO Capital Markets Underperform → Market Perform
모두보기

애브비 주식(ABBV)의 최신 뉴스

pulisher
01:45 AM

AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business

01:45 AM
pulisher
01:09 AM

AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters

01:09 AM
pulisher
10:47 AM

AbbVie Unit Wins $56 Million from Revance in Botox Patents Trial - Bloomberg Law News

10:47 AM
pulisher
12:11 PM

What drives AbbVie Inc. stock priceFree Technical Analysis Support - PrintWeekIndia

12:11 PM
pulisher
12:03 PM

AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest

12:03 PM
pulisher
Jul 20, 2025

Is AbbVie Inc. a good long term investmentMassive stock growth - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

AbbVie Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year - The Motley Fool

Jul 19, 2025
pulisher
Jul 19, 2025

AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks

Jul 19, 2025
pulisher
Jul 18, 2025

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch

Jul 18, 2025
pulisher
Jul 18, 2025

Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox

Jul 18, 2025
pulisher
Jul 17, 2025

Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Venetoclax Study in Greece: A Closer Look at CLL Treatment Outcomes - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Real-World Study on Upadacitinib for Crohn’s Disease: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Real-World Study on OZURDEX: A Closer Look at Market Implications - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Pediatric IBS-D Study: A Potential Game-Changer for Eluxadoline - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie Completes Phase 1 Trial of ALIA-1758: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie: Why I Set A $175 Buy Order (NYSE:ABBV) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma will turn cash positive with AbbVie's licensing deal S P - theweek.in

Jul 17, 2025
pulisher
Jul 17, 2025

Immunology Market Growth in Future Scope 2025-2032 | AbbVie - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie's (NYSE:ABBV) Investors Will Be Pleased With Their Strong 138% Return Over the Last Five Years - 富途牛牛

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025
pulisher
Jul 16, 2025

AbbVie’s Promising Study on Risankizumab for Crohn’s Disease: What Investors Need to Know - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AbbVie’s Promising Myelofibrosis Study: A Closer Look - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AbbVie’s Expanded Access to Fosigotifator: A Key Update for Investors - TipRanks

Jul 16, 2025

애브비 (ABBV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general JNJ
$163.28
price down icon 0.48%
drug_manufacturers_general NVS
$115.08
price up icon 0.71%
drug_manufacturers_general NVO
$64.78
price up icon 0.75%
drug_manufacturers_general MRK
$80.19
price up icon 0.00%
$295.04
price up icon 0.11%
자본화:     |  볼륨(24시간):